• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein One Launches Image Verify, Another Transformative Step Towards Achieving the Cleanest Claims in the Industry

    2/19/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email

    New Native, AI-Embedded Capability in Dentrix and Dentrix Ascend Helps Improve Image Quality Control at Capture

    Henry Schein One, the market leader in dental practice management systems, today announced the launch of AI-driven Image Verify, the latest innovation in a rapid series of product advancements designed to deliver the cleanest claims experience in dentistry. Image Verify, natively embedded in Dentrix and Dentrix Ascend, represents another major step towards the company's bold Clean Claims vision – a future where dental practices submit claims once and never have to touch them again.

    As the market leader in dental cloud-based technology, Henry Schein One has accelerated development across its platform to systematically eliminate friction points that lead to claim delays, denials, and costly rework. From Forms and Eligibility Pro to Voice Notes and a completely redesigned Claims Manager, each innovation is designed to reduce errors prior to submission and optimize the payment process. By natively combining these solutions, revenue cycle management is evolving – leading to fewer resubmissions, less time contacting insurers, and enabling practices to receive payments more quickly while reducing administrative demands.

    Image Verify is an AI-powered quality assessment tool built directly into the imaging work of Dentrix and Dentrix Ascend. It evaluates clinical images in real time at the moment of capture. By alerting teams to blur, misalignment, and incomplete coverage immediately, Image Verify helps prevent one of the most common and avoidable causes of claim denials.

    Up to 20% of dental claims are initially denied, contributing to an average practice revenue loss of 9% each year. Missing or low-quality images remain among the leading causes of these denials. By automating image verification at the source, Henry Schein One is eliminating upstream issues and reducing preventable errors.

    "Every year, the industry loses billions of dollars to preventable denials – from incomplete documentation to missing images to manual errors that require costly rework," said Dr. Ryan Hungate, Chief Clinical and Strategy Officer at Henry Schein One. "Image Verify is an important advancement, and it's part of a bigger mission. We've been reengineering the entire workflow inside Dentrix and Dentrix Ascend. Together, these innovations form a connected system to help eliminate errors before submission. That's how we make clean claims possible – helping practices reduce rework, avoid time-consuming calls to insurers, and accelerate reimbursement."

    Image Verify automatically reviews diagnostic dental images – such as bitewings and panoramic radiographs – to ensure they are clear and high quality. Team members can immediately determine whether image quality is sufficient, eliminating the need to interrupt appointments for retakes and allowing clinicians to focus more fully on patient care.

    The team at Great Lakes Dental Partners has adopted this new technology.

    "As we continue to modernize our revenue cycle workflows, tools like Image Verify represent a meaningful step forward," said Khuzaan Screwvalla, Vice President of IT at Great Lakes Dental Partners. "By improving image quality and documentation accuracy on the front end, all the while maintaining our single pane of glass ethos, we're able to submit cleaner claims, strengthen the patient experience, and drive greater consistency across our practices. It's a powerful foundation for scaling efficiently and confidently."

    Image Verify is among the latest Dentrix and Dentrix Ascend-native technologies designed to improve revenue cycle management. Additionally, Dentrix customers will receive access to the new Claims Manager this month, providing a centralized hub that streamlines claim review, improves visibility, and optimizes the overall claims management workflow.

    For more details about Image Verify and Henry Schein One's technology solutions for clean claims, visit www.henryscheinone.com. To learn more in person, connect with Henry Schein One at the Chicago Dental Society Midwinter Meeting, February 19–21, 2026, at Booth #3019, and join the company's happy hour from 4:00 to 5:00 PM CST on Thursday and Friday.

    About Henry Schein One

    Henry Schein One, the market leader in dental cloud-based technology, empowers dentists to focus on patient care and helps to ensure practice success. With simple and integrated technology, practices can become more efficient, profitable, and connected - leading to better experiences for patients and care teams alike. The company's comprehensive portfolio spans demand generation, patient experience, practice management, revenue cycle, analytics, and clinical workflow.

    Henry Schein One, LLC, is a joint venture between Henry Schein, Inc. (NASDAQ:HSIC) and Internet Brands. Its brands include Dentrix, Dentrix Ascend, Jarvis Analytics, TechCentral, Lighthouse360, and DentalPlans.com, as well as international brands such as Dentally and Software of Excellence.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260218846724/en/

    Media:

    Adam Beeson

    Sr. Manager of Communications, Henry Schein One

    [email protected]

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    2/23/2026$100.00Neutral → Outperform
    Robert W. Baird
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    More analyst ratings

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form 144 filed by Henry Schein Inc.

    144 - HENRY SCHEIN INC (0001000228) (Subject)

    3/19/26 12:30:49 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Henry Schein Inc.

    10-K - HENRY SCHEIN INC (0001000228) (Filer)

    2/24/26 4:42:20 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    2/24/26 6:14:45 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Henry Schein upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $100.00

    2/23/26 8:29:17 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Barclays initiated coverage on Henry Schein with a new price target

    Barclays initiated coverage of Henry Schein with a rating of Overweight and set a new price target of $86.00

    12/9/25 8:50:15 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Henry Schein from In-line to Outperform and set a new price target of $83.00

    8/26/25 8:13:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SEC Form 4 filed by Popeck Thomas C

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/20/26 4:07:39 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SVP & Chief Financial Officer South Ronald N. covered exercise/tax liability with 5,216 shares, decreasing direct ownership by 6% to 88,930 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/17/26 4:17:50 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SVP, Chief Human Res. Officer Sheehy Christine Zayac covered exercise/tax liability with 463 shares, decreasing direct ownership by 2% to 18,454 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/17/26 4:15:54 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein One Unveils the Next Era of Dentrix Ascend for DSOs and Growth-Focused Practices

    New Packages Accelerate Revenue Through an Integrated, Agentic Platform Henry Schein One, the market leader in dental practice management systems, today unveiled the next era of Dentrix Ascend—introducing three new packages built on a fully integrated, agentic platform architecture designed to help practices and Dental Service Organizations (DSOs) increase revenue and accelerate growth. The new offering strengthens Dentrix Ascend's position as the platform of choice for modern dental organizations while advancing Henry Schein One's strategy to unify practice management, clinical workflows, imaging, and revenue cycle management within a single intelligent platform. Momentum behind Dent

    3/10/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Participate in Upcoming Investor Conferences in March

    Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following conferences in March: Leerink's Global Healthcare Conference at the W South Beach hotel, Miami, on March 9, at 10:00 a.m. EST. Barclays 28th Annual Global Healthcare Conference at the Loews Miami Beach hotel, Miami, on March 10, at 10:30 a.m. EST. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc. (NASDAQ:HSIC) is a so

    3/3/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

    Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https://investors.biomerica.com/events-and-presentations/default.aspx IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today announced respo

    2/26/26 8:19:00 AM ET
    $BMRA
    $HSIC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical Specialities

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance

    Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particul

    2/24/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance

    Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in Q3 2024, and Q3 2025 non-GAAP diluted EPS of $1.38, compared to $1.22 non-GAAP diluted EPS in Q3 2024 Raises 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 and sales growth to 3-4% to reflect third quarter results Announces value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years Agreement reached to provide KKR the right to increase its HSIC stock ownership up to 19.9% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results

    11/4/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care